Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Lung neuroendocrine tumours (typical and atypical carcinoid), drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No randomised trial has tested somatostatin analogues or radioligand therapy specifically in lung neuroendocrine tumours.
Also on OnCo: Find a trial · Expert centres.
Lung and gastroenteropancreatic grading systems disagree, so trial eligibility and guideline advice do not map cleanly.
Atypical carcinoids relapse late and there is no proven adjuvant therapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
PFS HR 0.
A milestone in how this cancer is treated.
Closed early for slow recruitment; the underpowered comparison favoured lanreotide over placebo for progression-free survival.
A milestone in how this cancer is treated.